{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Kruzik A"],"funding":["Baxalta US Inc.","Baxalta Innovations GmbH"],"pubmed_abstract":["Preexisting immunity against adeno-associated virus (AAV) is a major challenge facing AAV gene therapy, resulting in the exclusion of patients from clinical trials. Accordingly, proper assessment of anti-AAV immunity is necessary for understanding clinical data and for product development. Previous studies on anti-AAV prevalence lack method standardization, rendering the assessment of prevalence difficult. Addressing this need, we used clinical assays that were validated according to guidelines for a comprehensive characterization of anti-AAV1, -AAV2, -AAV5, and -AAV8 immunity in large international cohorts of healthy donors and patients with hemophilia B. Here, we report a higher than expected average prevalence for anti-AAV8 (∼40%) and anti-AAV5 (∼30%) neutralizing antibodies (NAbs), whi"],"journal":["Molecular therapy. Methods & clinical development"],"pagination":["126-133"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6629972"],"repository":["biostudies-literature"],"pubmed_title":["Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors."],"pmcid":["PMC6629972"],"pubmed_authors":["de la Rosa M","Kruzik A","Fetahagic D","Dorn S","Horling FM","Hartlieb B","Scheiflinger F","Koppensteiner H","Reipert BM"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.","description":"Preexisting immunity against adeno-associated virus (AAV) is a major challenge facing AAV gene therapy, resulting in the exclusion of patients from clinical trials. Accordingly, proper assessment of anti-AAV immunity is necessary for understanding clinical data and for product development. Previous studies on anti-AAV prevalence lack method standardization, rendering the assessment of prevalence difficult. Addressing this need, we used clinical assays that were validated according to guidelines for a comprehensive characterization of anti-AAV1, -AAV2, -AAV5, and -AAV8 immunity in large international cohorts of healthy donors and patients with hemophilia B. Here, we report a higher than expected average prevalence for anti-AAV8 (∼40%) and anti-AAV5 (∼30%) neutralizing antibodies (NAbs), whi","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2026-05-07T01:05:23.41Z","creation":"2019-07-30T07:06:29Z"},"accession":"S-EPMC6629972","cross_references":{"pubmed":["31338384"],"doi":["10.1016/j.omtm.2019.05.014"]}}